Conversely, the percentages of reported bacterial infections and raised ALT and ALP cases in the tocilizumab arm are higher as compared to the control group, showing the adverse drug events and relatively lower safety profile of tocilizumab regarding the said indicative items (i.e., bacterial infections: 0.99% vs. 15.49%; ALT: 3.96% vs. 28.16%; and ALP: 1.98% vs. 22.53%). Here, GPT is linked to bacterial infectious disease.